No-Observed-Adverse-Effect Level
"No-Observed-Adverse-Effect Level" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The highest dosage administered that does not produce toxic effects.
| Descriptor ID |
D019055
|
| MeSH Number(s) |
E05.940.600 G07.690.936.750
|
| Concept/Terms |
No-Observed-Adverse-Effect Level- No-Observed-Adverse-Effect Level
- Level, No-Observed-Adverse-Effect
- Levels, No-Observed-Adverse-Effect
- No Observed Adverse Effect Level
- No-Observed-Adverse-Effect Levels
- NOAEL
No-Observed-Effect Level- No-Observed-Effect Level
- Level, No-Observed-Effect
- Levels, No-Observed-Effect
- No Observed Effect Level
- No-Observed-Effect Levels
Acceptable Daily Intake- Acceptable Daily Intake
- Acceptable Daily Intakes
- Daily Intake, Acceptable
- Daily Intakes, Acceptable
- Intake, Acceptable Daily
- Intakes, Acceptable Daily
- Tolerable Daily Intake
- Daily Intake, Tolerable
- Daily Intakes, Tolerable
- Intake, Tolerable Daily
- Intakes, Tolerable Daily
- Tolerable Daily Intakes
|
Below are MeSH descriptors whose meaning is more general than "No-Observed-Adverse-Effect Level".
Below are MeSH descriptors whose meaning is more specific than "No-Observed-Adverse-Effect Level".
This graph shows the total number of publications written about "No-Observed-Adverse-Effect Level" by people in this website by year, and whether "No-Observed-Adverse-Effect Level" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "No-Observed-Adverse-Effect Level" by people in Profiles.
-
Tetrahydrofurandiols (THF-diols), leukotoxindiols (LTX-diols), and endocrine disruption in rats. Environ Health Perspect. 2007 May; 115(5):702-8.
-
CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):1034-6.
-
Developmental consequences of in utero sodium arsenate exposure in mice with folate transport deficiencies. Toxicol Appl Pharmacol. 2005 Feb 15; 203(1):18-26.